Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177498 · ClinicalTrials.gov registry record · Early Phase 1
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
A Early Phase 1 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04177498 is a Early Phase 1 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 3 participants.
The verdict
NCT04177498, a Early Phase 1 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Rigosertib Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2025-05-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177498
The ClinicalTrials.gov registry entry for NCT04177498 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04177498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177498 about?
NCT04177498 is a clinical study titled "Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC". This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.
What is the current status of trial NCT04177498?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2021-08-24. Estimated completion is 2025-05-05.
What interventions are being tested in trial NCT04177498?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Rigosertib Sodium (DRUG).
Who is sponsoring clinical trial NCT04177498?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.